Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Aug. 30, 2024	Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes	Sustainability
Aug. 07, 2024	Posted Conference on Q1 FY2024 Financial Results [Webcast]	Finances
Aug. 07, 2024	Sumitomo Pharma Announces Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan	Products
Aug. 07, 2024	【Joint press release】Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan	Products
Aug. 05, 2024	First Transplantation in Phase 1/2 Study of Allogeneic iPS Cell-Derived Retinal Pigment Epithelial Cells	R&D
Jul. 31, 2024	Presentation Material (Conference on Q1 FY2024 Financial Results)（PDF/957KB）	Finances

Oct. 30, 2024	Announcement of second quarter FY2024 financial results, conference on second quarter FY2024 financial results for institutional investors, analysts, and the press (planned, 1:30 p.m.)